Oxybenzone

Summary

Oxybenzone (CHEMBL1625) is an approved small-molecule dermatologic drug; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 228.24 Da · C14H12O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1625
Name	Oxybenzone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4632
ChEBI	CHEBI:34283
Molecular formula	C14H12O3
Molecular weight	228.24
InChIKey	DXGLGDHPHMLXJC-UHFFFAOYSA-N

SMILES: COC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O

IUPAC name: (2-hydroxy-4-methoxyphenyl)-phenylmethanone

ChEBI definition: A hydroxybenzophenone that is benzophenone which is substituted at the 2- and 4-positions of one of the benzene rings by hydroxy and methoxy groups respectively.

Pharmacological roles (ChEBI): dermatologic drug, protective agent, ultraviolet filter.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Advastab 45, Benzophenone-3, NSC-7778, Ongrostab hmb, Oxibenzona, Oxybenzone, Oxybenzone component of shade uvaguard, Tinosorb b 3, Uvinul 40, Viosorb 110, oxybenzone, SID11112288

Patent coverage: 20,561 distinct patent families (57,990 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 57,366 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Prelamin-A/C, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Progesterone receptor, Sodium-dependent noradrenaline transporter, Histamine H1 receptor, Sodium-dependent dopamine transporter, 3’,5’-cyclic-AMP phosphodiesterase 4A, 3’,5’-cyclic-AMP phosphodiesterase 4D, Cytochrome P450 2D6, Cytochrome P450 1A2, Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19, Mitogen-activated protein kinase 1, Huntingtin, Hormone-sensitive lipase.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 21 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	6.4	Potency	398.1	nM	CHEMBL_ACT_4020525
CYP2C19	6.4	AC50	398.1	nM	CHEMBL_ACT_6004199
CYP1A2	5.8	AC50	1585	nM	CHEMBL_ACT_6007402
P15304	5.49	IC50	3250	nM	CHEMBL_ACT_2370405
HPGD	5.05	Potency	8912	nM	CHEMBL_ACT_4784740

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).